Core Insights - Gain Therapeutics, Inc. announced that a late-breaking abstract on GT-02287 has been accepted for presentation at the FENS Forum 2024, highlighting cognitive performance improvements in a preclinical model of GBA1 Parkinson's disease [1][2] Company Overview - Gain Therapeutics is a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies [6] - The lead drug candidate, GT-02287, is in clinical development for GBA1 Parkinson's disease and is currently undergoing a Phase 1 clinical trial [6] Drug Candidate Details - GT-02287 is an orally administered, brain-penetrant small molecule that acts as an allosteric protein modulator, restoring the function of the lysosomal enzyme glucocerebrosidase (GCase) impaired by GBA1 gene mutations [4] - In preclinical models, GT-02287 has shown to restore GCase function, reduce aggregated α-synuclein, decrease neuroinflammation and neuronal death, increase dopamine levels, and improve both motor function and cognitive performance [4] - The drug also significantly reduced plasma neurofilament light chain (NfL) levels, a biomarker for neurodegeneration [4] Funding and Support - Gain Therapeutics has received funding support from The Michael J. Fox Foundation for Parkinson's Research, The Silverstein Foundation for Parkinson's with GBA, and the Eurostars-2 joint program co-funded by the European Union Horizon 2020 research and Innosuisse [5] Research and Development Platform - The company utilizes the Magellan™ drug discovery platform, which leverages AI-supported structural biology and supercomputer-powered models to identify novel allosteric binding sites on disease-implicated proteins [7] - This platform enhances the original SEE-Tx® platform with new AI and machine-learning tools, allowing access to a vast chemical space of over five trillion compounds [7][8] Event Details - The poster presentation at the FENS Forum will take place on June 27, 2024, at 11:30 am, focusing on the improvements in daily living activities and cognitive performance due to GT-02287 [2]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40237 GAIN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 85-1726310 (Sta ...

Exhibit 99.1 Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update BETHESDA, Md., May 14, 2024 – Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended March 31, 2024, and provides a corporate update. Corporate Highlights from Q1 2024 to Date "Gain continues to b ...

BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces positive results from the single ascending dose (SAD) part of its Phase 1 study. GT-02287 was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events. The good safety and tolerability ...

Shares of Gain Therapeutics, Inc. (GANX) have been struggling lately and have lost 6.5% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the f ...

A downtrend has been apparent in Gain Therapeutics, Inc. (GANX) lately with too much selling pressure. The stock has declined 25.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical ind ...

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024. "We are thrilled to welcome Gene as our new CFO," commented Gain CEO Matthias Alder. "His experience as an operational CFO with a track record ...

DOCUMENTS INCORPORATED BY REFERENCE Portions of the definitive Proxy Statement ("Proxy Statement") of Gain Therapeutics, Inc. to be filed pursuant to Regulation 14A of the general rules and regulations under the Securities Exchange Act of 1934, as amended, for the 2024 annual meeting of stockholders to be held within 120 days after the end of the Registrant's 2023 fiscal year are incorporated by reference into Part III of this Form 10-K. Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHA ...

Exhibit 99.1 Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update BETHESDA, Md., March 26, 2024 – Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the year ended December 31, 2023 and provides a corporate update. Corporate Highlights from Q4 2023 to Date "With the tremendous pro ...

BETHESDA, Md., March 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 at Old Parkland in Dallas, TX. Public Ventures Discovery DayDate: Tuesday, March 19, 2024Presentation: 2:30 PM CSTLocation: Pecan Room, Old Parkland, 3819 Maple A ...